Physician profile
Ting-Yu Wang
NPI 1780146431
$3,103.61
in general payments reported to CMS, 2019-2025
18 companies · $813 in 2025
The $813 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.20 · 2023: $321 · 2024: $1,919 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806 · Grant: $1,063 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.37 |
| Grant | $1,063.29 |
| Education | $182.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,262.86 | 2023-2024 | Avvigo Guidance System |
| Medtronic, INC. | $582.58 | 2023-2025 | Onyx Frontier, Resolute Onyx, Linq II |
| Shockwave Medical, INC | $315.16 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $206.17 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $143.08 | 2025 | Assure Wcd |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Amgen INC. | $115.35 | 2024-2025 | Repatha |
| Pfizer INC. | $51.20 | 2022 | |
| Lantheus Medical Imaging, INC. | $50.67 | 2023-2024 | Definity |
| Merck Sharp & Dohme LLC | $47.99 | 2023-2024 | Verquvo |
| Celgene Corporation | $31.71 | 2024 | Zeposia |
| Glaxosmithkline, LLC. | $31.12 | 2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $24.29 | 2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $22.42 | 2023 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $21.50 | 2024 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $20.23 | 2023 | Kengreal |
| Philips North America LLC | $17.29 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $16.99 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting-Yu Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.